Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-०.२१%
१,०९१.५१
-२.३०
-०.२१%
—१,०९३.८११,०९६.५२१,१००.२२१,०९१.५१——
SIXC
Communications
SIXC
Communications
SIXC
+०.२२%
६१०.११
+१.३४
+०.२२%
—६०८.७७६०८.७७६१२.९७६०८.७७——
SIXE
Energy
SIXE
Energy
SIXE
-१.३४%
१,२३७.९८
-१६.८३
-१.३४%
—१,२५४.८११,२५३.०११,२५३.८७१,२२६.३३——
SIXI
Industrials
SIXI
Industrials
SIXI
-०.९३%
१,७४४.७१
-१६.४०
-०.९३%
—१,७६१.१११,७६४.२७१,७६६.८८१,७४४.७१——
SIXM
Financials
SIXM
Financials
SIXM
-०.३७%
६४०.१८
-२.४०
-०.३७%
—६४२.५८६४४.८७६४८.४८६४०.१८——
SIXR
Staples
SIXR
Staples
SIXR
-०.१८%
८४९.५८
-१.५५
-०.१८%
—८५१.१३८५५.६६८५८.७५८४५.५६——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-०.२३%
२१७.४८
-०.५०
-०.२३%
—२१७.९८२१७.९८२१८.६५२१६.८८——
SIXT
Technology
SIXT
Technology
SIXT
+१.५२%
३,२६०.६९
+४८.८६
+१.५२%
—३,२११.८३३,२२७.२१३,२६८.३८३,२२६.५५——
SIXU
Utilities
SIXU
Utilities
SIXU
-०.६९%
९४२.४५
-६.५३
-०.६९%
—९४८.९८९४८.५८९५७.८३९४१.९७——
SIXV
Health care
SIXV
Health care
SIXV
-०.५२%
१,४६६.८०
-७.७२
-०.५२%
—१,४७४.५२१,४७९.०३१,४८१.०४१,४६६.८०——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+०.२२%
२,३९७.५०
+५.३८
+०.२२%
—२,३९२.१२२,३९६.९५२,४२१.२२२,३८२.३२——
Q1 2026 earnings • in 2 days
See details
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
US$ २४.७७
+०.३२%
(+०.०८०) 1D
US$ २४.६९
-०.३२% (-०.०८०)
After hours
Closed: मे १, १६:००:०० GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RARE...
Open
US$ २४.९०
High
US$ २५.१२
Low
US$ २४.३६
Mkt. cap
२.४४ अरब
Avg. vol.
२०.४० लाख
Volume
१४.०७ लाख
52-wk high
US$ ४२.३७
52-wk low
US$ १८.२९
EPS
-US$ ५.८३
Beta
०.२५
Shares outstanding
९.८३ करोड
No. of employees
१ हजार
News stories
From sources across the web
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases. Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami. Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Employees१.३७ हजार
Founded२०१०
HeadquartersNovato, क्यालिफोर्निया, संयुक्त राज्य अमेरिका
Sector-
Websiteultragenyx.com
Next call २ दिनमा
मे ५, मङ्गल, १७:००
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-/ (-१.४६ est.)USD
Revenue / Estimate
-/ (१५.८४ करोड est.)USD
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earningsInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
२०२५ मार्च
२०२५ जुन
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
Revenue
१३.९३ करोड
१६.६५ करोड
१५.९९ करोड
२०.७३ करोड
Cost of goods sold
१९.४४ करोड
१८.७७ करोड
२४.४२ करोड
२३.२६ करोड
Cost of revenue
१९.४४ करोड
१८.७७ करोड
२४.४२ करोड
२३.२६ करोड
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
८.७८ करोड
८.६६ करोड
८.६६ करोड
८.७९ करोड
Operating expense
८.७८ करोड
८.६६ करोड
८.६६ करोड
८.७९ करोड
Total operating expenses
२८.२२ करोड
२७.४४ करोड
३३.०८ करोड
३२.०६ करोड
Operating income
-१४.२९ करोड
-१०.७९ करोड
-१७.०९ करोड
-११.३३ करोड
Other non operating income
८.३७ लाख
२१.४० लाख
-१०.४३ लाख
-९.३४ लाख
EBT including unusual items
-१४.९८ करोड
-११.४० करोड
-१७.९५ करोड
-१२.७७ करोड
EBT excluding unusual items
-१४.९६ करोड
-११.४० करोड
-१८.०२ करोड
-१२.७२ करोड
Income tax expense
१३.१० लाख
९.४७ लाख
८.७३ लाख
८.७० लाख
Effective tax rate
-०.८७%
-०.८३%
-०.४९%
-०.६८%
Other operating expenses
-
-
-
-
Net income
-१५.११ करोड
-११.५० करोड
-१८.०४ करोड
-१२.८६ करोड
Net profit margin
-१०८.४६%
-६९.०४%
-११२.८१%
-६२.०२%
Earnings per share
-१.५७
-१.१७
-१.८१
-१.२९
Interest and investment income
६८.३१ लाख
५७.९४ लाख
५८.६३ लाख
६५.१२ लाख
Interest expense
-१.४३ करोड
-१.४० करोड
-१.४१ करोड
-१.९५ करोड
Net interest expenses
-७५.११ लाख
-८२.४७ लाख
-८२.८५ लाख
-१.३० करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
-१३.३९ करोड
-९.९३ करोड
-१६.२३ करोड
-१०.४५ करोड
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer